CLYM Stock Analysis: Climb Bio | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 739m USD | 12M Return: 965.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.8M
Warnings
Tailwinds
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Climb Bio, Inc. (NASDAQ: CLYM) is a U.S.-based clinical-stage biotechnology company headquartered in Wellesley Hills, Massachusetts, focused on developing therapies for immune-mediated diseases with limited treatment options. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody currently in Phase 2 trials for primary membranous nephropathy and immune thrombocytopenia, with a Phase 1b trial underway for systemic lupus erythematosus. The company is also advancing CLYM116, a preclinical anti-APRIL monoclonal antibody aimed at IgA nephropathy and other B-cell mediated diseases. The company was incorporated in 2018 (formerly Eliem Therapeutics, rebranded in October 2024) and, like most clinical-stage biotechs, is pre-revenue and dependent on capital markets and future partnerships to fund its R&D pipeline, with monoclonal antibodies representing the core of its therapeutic platform targeting B-cell driven autoimmune conditions.
- Budoprutug Phase 2 data readout in membranous nephropathy approaches
- CLYM116 anti-APRIL antibody advances toward IND filing
- Cash burn rate raises near-term dilutive financing risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -20.57 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.35 > 3% & CFO -53.3m > Net Income -52.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 27.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.2m) vs 12m ago 1.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.72 (Total Current Assets 113.4m - Total Current Liabilities 4.07m) / Total Assets 152.4m |
| B: -1.99 (Retained Earnings -303.4m / Total Assets 152.4m) |
| C: -0.30 (EBIT TTM -52.8m / Avg Total Assets 176.6m) |
| D: 34.54 (Book Value of Equity 148.1m / Total Liabilities 4.29m) |
| Altman-Z'' = 32.48 = AAA |
As of July 08, 2026, the stock is trading at USD 13.42 with a total of 1,365,731 shares traded. Over the past week, the price has changed by +0.45%, over one month by +24.61%, over three months by +95.34% and over the past year by +965.08%.
Current recommended Stop Loss: 11.40 (which is 15.1% or 2.1 ATR below the current price).
Climb Bio has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy CLYM.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.9 | 56% |
P/B = 5.1391
Revenue TTM = 0.0 USD
EBIT TTM = -52.8m USD
EBITDA TTM = -52.7m USD
Long Term Debt = 216k USD (estimated: total debt 479k - short term 263k)
Short Term Debt = 263k USD (from shortTermDebt, last quarter)
Debt = 479k USD (from shortLongTermDebtTotal, last quarter) (leases 479k already included)
Net Debt = -109.1m USD (calculated: Debt 479k - CCE 109.6m)
Enterprise Value = 629.6m USD (738.7m + Debt 479k - CCE 109.6m)
Interest Coverage Ratio = unknown (Ebit TTM -52.8m / Interest Expense TTM 0.0)
EV/FCF = -11.77x (Enterprise Value 629.6m / FCF TTM -53.5m)
FCF Yield = -8.50% (FCF TTM -53.5m / Enterprise Value 629.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 135k) / Revenue TTM)
Tobins Q-Ratio = 4.13 (Enterprise Value 629.6m / Total Assets 152.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 479k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -41.7m (EBIT -52.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 27.86 (Total Current Assets 113.4m / Total Current Liabilities 4.07m)
Debt / Equity = 0.00 (Debt 479k / totalStockholderEquity, last quarter 148.1m)
Debt / EBITDA = 2.07 (negative EBITDA) (Net Debt -109.1m / EBITDA -52.7m)
Debt / FCF = 2.04 (negative FCF - burning cash) (Net Debt -109.1m / FCF TTM -53.5m)
Total Stockholder Equity = 167.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -29.90% (Net Income -52.8m / Total Assets 152.4m)
RoE = -31.46% (Net Income TTM -52.8m / Total Stockholder Equity 167.8m)
RoCE = -31.41% (EBIT -52.8m / Capital Employed (Equity 167.8m + L.T.Debt 216k))
RoIC = -28.07% (negative operating profit) (NOPAT -41.7m / Invested Capital 148.6m)
WACC = 7.54% (E(738.7m)/V(739.2m) * Re(7.54%) + D(479k)/V(739.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.06 | Cagr: 50.76%
[DCF] Fair Price = unknown (Cash Flow -53.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.75 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.22 | Chg30d=+0.00% | Revisions=+62% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.21 | Chg30d=+0.00% | Revisions=+62% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.87 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+1.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.12 | Chg30d=+0.00% | Revisions=+22% | GrowthEPS=-29.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +71% (up=19, down=2)